Back to News
Market Impact: 0.3
Myriad Genetics Surge On $210 Mln Prenatal Testing Business Sale To Labcorp
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Myriad Genetics agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash, plus the value of inventory at closing. The available report provides no further terms or information about the transaction’s expected financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
LH0.30
MYGN0.20
More News
- Why is Myriad Genetics stock surging today?
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports
- This Janus Henderson fund manager owns CoreWeave debt — here's why he's sticking with it